305 related articles for article (PubMed ID: 26231047)
1. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
Nguyen M; Cencic R; Ertel F; Bernier C; Pelletier J; Roulston A; Silvius JR; Shore GC
BMC Cancer; 2015 Aug; 15():568. PubMed ID: 26231047
[TBL] [Abstract][Full Text] [Related]
2. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
3. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
[TBL] [Abstract][Full Text] [Related]
7. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
8. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
9. Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax.
Shamas-Din A; Bindner S; Chi X; Leber B; Andrews DW; Fradin C
Biochem J; 2015 May; 467(3):495-505. PubMed ID: 25714678
[TBL] [Abstract][Full Text] [Related]
10. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Okumura K; Sinicrope FA
Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
[TBL] [Abstract][Full Text] [Related]
11. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
12. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043
[TBL] [Abstract][Full Text] [Related]
13. BIM and tBID are not mechanistically equivalent when assisting BAX to permeabilize bilayer membranes.
Terrones O; Etxebarria A; Landajuela A; Landeta O; Antonsson B; Basañez G
J Biol Chem; 2008 Mar; 283(12):7790-803. PubMed ID: 18195012
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
Trudel S; Li ZH; Rauw J; Tiedemann RE; Wen XY; Stewart AK
Blood; 2007 Jun; 109(12):5430-8. PubMed ID: 17332241
[TBL] [Abstract][Full Text] [Related]
15. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
16. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA
Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880
[TBL] [Abstract][Full Text] [Related]
17. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
18. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies.
Kim H; Rafiuddin-Shah M; Tu HC; Jeffers JR; Zambetti GP; Hsieh JJ; Cheng EH
Nat Cell Biol; 2006 Dec; 8(12):1348-58. PubMed ID: 17115033
[TBL] [Abstract][Full Text] [Related]
19. Marinopyrrole derivatives with sulfide spacers as selective disruptors of Mcl-1 binding to pro-apoptotic protein Bim.
Cheng C; Liu Y; Balasis ME; Garner TP; Li J; Simmons NL; Berndt N; Song H; Pan L; Qin Y; Nicolaou KC; Gavathiotis E; Sebti SM; Li R
Mar Drugs; 2014 Jul; 12(8):4311-25. PubMed ID: 25076060
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]